Indications
Therapeutic Asset Ratings
6,308 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
mt-4561
Head And Neck Squamous Cell Carcinoma
Tanabe Pharma America, Inc.
P1/2
CC
(47)
Nadravaleucel
Cancer
BOE Technology Group Co., Ltd.
P1/2
CC
(47)
Nadravaleucel
Metastatic Neoplasm
NKGen Biotech, Inc.
P1/2
CC
(47)
Nadravaleucel
Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
P1/2
CC
(47)
Naltrexone
Immune Dysregulation, Autoimmunity, And Autoinflammation
Truway Health, Inc.
P1/2
CC
(47)
Navitoclax
Melanoma
National Cancer Institute (NCI)
P1/2
CC
(47)
Naxitamab
Her2-Receptor Negative Breast Cancer
Margaret Gatti-Mays
P1/2
CC
(47)
NC 410
Head And Neck Cancer
NextCure, Inc.
P1/2
CC
(47)
Neoantigen Specific Tcr-T Cell Drug Product
Squamous Cell Lung Carcinoma
Alaunos Therapeutics
P1/2
CC
(47)
New Donor-Derived Cd7 Car T-Cell
T-Cell And NK-Cell Neoplasm
Beijing GoBroad Hospital
P1/2
CC
(47)
Nivestim
Beta Thalassemia
National Heart, Lung, and Blood Institute (NHLBI)
P1/2
CC
(47)
np137
Acute Myeloid Leukemia
Centre Leon Berard
P1/2
CC
(47)
Ntx-301
Malignant Glioma
Xennials Therapeutics Australia Pty Ltd
P1/2
CC
(47)
Olaparib
Metastatic Malignant Neoplasm In The Brain
Colette Shen
P1/2
CC
(47)
Olaparib
Esthesioneuroblastoma
Fundación de investigación HM
P1/2
CC
(47)
Olaparib
Meningioma
Fundación de investigación HM
P1/2
CC
(47)
Olaparib
Paraganglioma
Fundación de investigación HM
P1/2
CC
(47)
Olaparib
Pheochromocytoma
Fundación de investigación HM
P1/2
CC
(47)
Olomorasib
Biliary Tract Neoplasm
Eli Lilly and Company
P1/2
CC
(47)
Olverembatinib
Myeloid Neoplasm
Ascentage Pharma Group Inc.
P1/2
CC
(47)
Olvi-Vec
Small Cell Lung Carcinoma
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
P1/2
CC
(47)
Oncolytic Virus Rp1
Triple-Negative Breast Carcinoma
Institut Curie
P1/2
CC
(47)
Onivyde
Cancer
St. Jude Children's Research Hospital
P1/2
CC
(47)
Orca-Q
Acute Undifferentiated Leukemia
University of Florida
P1/2
CC
(47)
Osemitamab
Gastroesophageal Junction Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
P1/2
CC
(47)
Showing 2501 to 2525 of 6,308 assets
Previous
Page 101 of 253
Next